Home>Topics>Stocks>Biomarin Pharmaceutical

Biomarin Pharmaceutical BMRN

  1. All
  2. Commentary
  3. Stock Reports
  4. Headlines
    1. New Morningstar Analyst Report for Biomarin Pharmaceutical , Inc.

      Stock Reports

      Fri, 11 Apr 2014

      BioMarin's Vimizim should boost top-line growth and bring the firm to profitability.

    2. Cramer's Lightning Round - The IPOs Are A Curse On The Market (4/10/14)

      Headlines

      Fri, 11 Apr 2014

      By SA Editor Miriam Metzinger : Stocks discussed on the Lightning Round segment of Jim Cramer's Mad Money Program, Thursday April 10. Bullish Calls: Service Corporation ( SCI ): "We have been faithful to Service Corporation in the funeral home industry. We will stick with that one. It is a very ...

    3. Avoid Applied Genetic Technologies IPO

      Headlines

      Wed, 26 Mar 2014

      By Don Dion : Applied Genetic Technologies Corp ( AGTC ), a clinical-stage biotechnology firm, developing treatments for severe inherited diseases of the eye, plans to raise $50.0 million in its upcoming IPO. The Alachua, Florida-based firm will offer 3.6 million shares at an expected price range

    4. UniQure IPO Could Heal What Ails Investors In 2014

      Headlines

      Tue, 4 Feb 2014

      By Don Dion : UniQure BV ( QURE ), a leading gene therapy biopharmaceutical firm, with principal offices in Amsterdam, plans to raise $64 million in its upcoming IPO. The firm will offer 4.6 million shares at an expected price range of $13-$15 per share. If the IPO can reach the midpoint of that ...

    5. Ultragenyx Pharmaceuticals IPO Likely To Yield Investors Rewards

      Headlines

      Thu, 30 Jan 2014

      By Don Dion : The RARE IPO Deal Ultragenyx Pharmaceutical ( RARE ), a development-stage biopharm firm, focused on the development of treatments for rare and ultra-rare diseases, plans to raise $94 million in its upcoming IPO on Friday, January 31. The Novato, California-based firm will offer 4.8 ...

    6. Cramer's Lightning Round - Stay Long Kinder Morgan Partners (1/21/14)

      Headlines

      Wed, 22 Jan 2014

      think there will be huge charges because of the lawsuits. It is the best performer of the large cap oils. This is the one to buy of the majors." BioMarin ( BMRN ), Biogen Idec ( BIIB ), Gilead ( GILD ): "I think BMRN can Complete Story »

    7. Cramer's Lightning Round - No Mere Finger Waving At Michael Kors (1/8/14)

      Headlines

      Thu, 9 Jan 2014

      reviewed it after it fell apart. The stock is a wild trader, but the business is secure. We are not backing away." BioMarin ( BMRN ), NPS Pharmaceuticals ( NPSP ): Cramer prefers these stocks to MannKind. Genuine Parts ( GPC ): "It is a very good, consistent

    8. Cramer's Lightning Round - The Quintessential American Stock That Is Going To Work (12/9/13)

      Headlines

      Tue, 10 Dec 2013

      HVAC (heating, ventilation and air conditioning) is one of the strongest currents right now in the action." BioMarin ( BMRN ): "They did a financing, and that has knocked the stock down. I still like that stock." FedEx ( FDX ), UPS ( UPS

    9. Cramer's Mad Money - Who's Next In Biotech? (8/27/13)

      Headlines

      Wed, 28 Aug 2013

      Gilead ( GILD ), Novartis ( NVS ), Johnson & Johnson ( JNJ ), Medivation ( MDVN ), Seattle Genetics ( SGEN ), BioMarin ( BMRN ) Amgen ( AMGN ) announced it is buying Onyx Pharmaceuticals ( ONXX ) at a 50% premium, and the deal is a win-win for both

    10. Cramer's Mad Money - Noodles & Company Is The Son Of Chipotle (7/1/13)

      Headlines

      Tue, 2 Jul 2013

      By SA Editor Miriam Metzinger : Stocks discussed on the in-depth session of Jim Cramer's Mad Money TV Program, Monday July 1. Noodles & Company ( NDLS ). Other stock mentioned: Chipotle Mexican Grill ( CMG ) Noodles & Company ( NDLS ) was a red hot IPO that might go higher on a new food trend. It

    « Prev12345Next »
    Content Partners